ApoB: The Missing Piece in the Cholesterol Puzzle
The American Heart Association and American College of Cardiology’s updated cholesterol guidelines in March 2026 acknowledged apolipoprotein B (apoB) as a potentially more precise marker of cardiovascular risk. However, they stopped short of recommending apoB as the primary method for testing, instead continuing to prioritize LDL cholesterol. This mirrors the cautious approach taken by the European Atherosclerosis Society, which has reflected apoB’s usefulness in its guidelines for years, yet has not seen widespread adoption in routine care.
This inertia is largely due to the success of LDL cholesterol as a scientific breakthrough and public health success story. LDL cholesterol has been directly linked to treatments that work, and its simplicity has made it widely understood. However, this simplicity has also limited how risk is understood, with patients and physicians knowing little or nothing about apoB. Allan Sniderman, a cardiologist at McGill University, notes that apoB testing can be done through standard blood tests, yet it has not filtered into routine care.
The challenge lies in understanding what each marker captures and what it misses. ApoB reflects the total number of cholesterol-carrying particles in the blood, but not their source. LDL makes up most of these particles, but lipoprotein(a) and triglyceride-rich particles also play a role. Kausik Ray, a cardiologist at Imperial College London, emphasizes that apoB may be a better overall signal of risk, but clinicians still need to understand what is driving it.
The Decision Logic Behind ApoB Adoption
Despite the growing body of research suggesting apoB is a more accurate marker of cardiovascular risk, its adoption has been slow. This is largely due to the existing infrastructure and guidelines that prioritize LDL cholesterol. The pharmaceutical industry has also played a significant role in promoting LDL-lowering treatments, which have been highly effective in reducing heart attacks and strokes.
However, researchers are beginning to explore more granular ways of measuring risk, including the use of metabolic and genetic data. This shift is not just about better markers, but earlier detection. Cardiovascular risk builds silently over decades, yet testing often begins only once symptoms or clear risk factors appear.
The decision-making logic behind apoB adoption is complex, involving internal incentives, investor pressure, regulatory risk, and competitive threat. Pharmaceutical companies have a vested interest in promoting LDL-lowering treatments, while clinicians may be hesitant to adopt new markers that require additional training and infrastructure.
Winners and Losers in the ApoB Shift
The shift towards apoB as a primary marker of cardiovascular risk will have significant implications for various stakeholders. Pharmaceutical companies that have invested heavily in LDL-lowering treatments may see their market share decline. On the other hand, companies that develop apoB-targeting treatments may see significant growth opportunities.
Clinicians who adopt apoB testing may see improved patient outcomes, but may also face additional costs and analytical burdens. Patients who are identified as high-risk through apoB testing may require more aggressive treatment, which can be costly and have significant side effects.
The shift towards apoB will also have significant implications for healthcare systems, which will need to adapt to new testing protocols and treatment guidelines. This may require significant investments in infrastructure and training, but may ultimately lead to improved patient outcomes and reduced healthcare costs.
The Skeptical Case Against ApoB
While apoB has been shown to be a more accurate marker of cardiovascular risk, there are still significant limitations to its adoption. One of the primary concerns is the cost and complexity of apoB testing, which may be prohibitively expensive for many healthcare systems.
Additionally, apoB testing may not be as widely available as LDL cholesterol testing, which could limit its adoption in routine care. Furthermore, apoB testing may not be as well-understood by clinicians, which could lead to misinterpretation of results and inappropriate treatment.
The Signal to Watch Next
The next significant event to watch in the apoB story is the publication of the results of the ongoing trials evaluating the effectiveness of apoB-targeting treatments. These trials will provide critical evidence on the safety and efficacy of apoB-targeting treatments and will likely shape the future of cardiovascular risk assessment and treatment.
Additionally, the development of new apoB testing protocols and technologies will be an important area to watch. Advances in apoB testing may make it more widely available and affordable, which could accelerate its adoption in routine care.
Pick one tactic from this post and apply it today. Which one will you start with?
By Daniel Cross, Digital Growth Strategist at TrendFlashy
Ready to launch your own asset?
Check out our guide on Building a Profitable Online Business.
